# EDGAR Filing Document

**Accession Number:** 0001194459
**File Stem:** 0001194459-26-000001
**Filing Date:** 2026-3
**Character Count:** 7679
**Document Hash:** 1808ec1860384c87b08c9414678f1850
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001194459-26-000001.hdr.sgml**: 20260305

**ACCESSION NUMBER**: 0001194459-26-000001

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260303

**FILED AS OF DATE**: 20260305

**DATE AS OF CHANGE**: 20260305

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DOYLE WILLIAM F
- **CENTRAL INDEX KEY:** 0001194459

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37565
- **FILM NUMBER:** 26726630

**MAIL ADDRESS:**
- **STREET 1:** 180 HANOVER ST.
- **CITY:** PORTSMOUTH
- **STATE:** NH
- **ZIP:** 08301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NovoCure Ltd
- **CENTRAL INDEX KEY:** 0001645113
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 4 THE FORUM
- **STREET 2:** GRENVILLE STREET
- **CITY:** ST. HELIER
- **PROVINCE COUNTRY:** Y9
- **BUSINESS PHONE:** 44 (0)15 3475 6700

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** NO. 4 THE FORUM
- **STREET 2:** GRENVILLE STREET
- **CITY:** ST. HELIER
- **PROVINCE COUNTRY:** Y9

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Novocure Ltd
- **DATE OF NAME CHANGE:** 20150615

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DOYLE WILLIAM F<br><sub>(Last) (First) (Middle)</sub><br>C/O NOVOCURE INC.<br>1550 LIBERTY RIDGE DRIVE, SUITE 115<br><sub>(Street)</sub><br>WAYNE, PA 19087<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Executive Chairman_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>NovoCure Ltd [ NVCR ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Ordinary Shares<sup>(1)</sup> | 2026-03-03 |  | A |  | 200000.00 | A | $0.00 | 200000.00 | D |  |
| Ordinary Shares<sup>(2)</sup> | 2026-03-03 |  | A |  | 200284.00 | A | $0.00 | 400284.00 | D |  |
| Ordinary Shares | 2026-03-03 |  | S |  | 50557.00<sup>(3)</sup> | D | 12.7865<sup>(4)</sup> | 349727.00 | D |  |
| Ordinary Shares | 2026-03-03 |  | S |  | 21330.00<sup>(3)</sup> | D | 13.4288<sup>(5)</sup> | 328397.00 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | $13.30 | 2026-03-03 |  | A |  | 258445.00 |  | <sup>(6)</sup> | 2036-03-03 | Ordinary Shares | 258445.00 | $0.00 | 258445.00 | D |  |
| Stock Option (Right to Buy) | $13.30 | 2026-03-03 |  | A |  | 30072.00 |  | <sup>(6)</sup> | 2036-03-03 | Ordinary Shares | 30072.00 | $0.00 | 288517.00 | D |  |

---

### Footnotes:

(1) Represents restricted share units that are scheduled to vest in equal  parts on the first, second and third  anniversary of the grant date, subject to the reporting person's continued employment through such dates.

(2) Represents vesting of performance-based restricted stock units.

(3) Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance-Based Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

(4) This transaction was executed in multiple trades at prices ranging from $12.299 USD to $13.277 USD; the price reported above reflects the weighted average sale price.

(5) This transaction was executed in multiple trades at prices ranging from $13.35 USD to $13.52 USD; the price reported above reflects the weighted average sale price.

(6) Options to buy ordinary shares that are scheduled to vest in equal parts on the first, second, third and fourth anniversary of the grant date, subject to the reporting person's continued employment through such date.

**Signature:** Steven Robbins, as attorney in fact for Doyle, William F  
**Date:** 2026-03-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**